press. ' 17. Trafford J.A.P., jones R.H., Evans R., Sharp P., Sharpstone P., Cook J.:~ancet, 2, 1453-1456, 1977. Hemoperfusion in chronic sch izoph ren ia (1) reported the treatment of 6 chronic schizophrenic patients with weekly hemodialysis for 16 times or more. This treatment was reported to have resulted in marked improvements in 5 patients. More recently, they (2) reported the use of hemodialysis in a total of 23 patients. In 16 patients, improvements have been dramatic with complete disappearance of the manifestation of schizophrenia. They further found that in 7 out of 10 patients,~-endorphin has been found in high concentrations in the first dialysate, and much lower in the dialysate of subsequent dialysis, correlating with the improvement of the patients. Earlier studies in animals by another group, have shown that intracerebrospinal fluid injection of endorphins into rats have resulted in changes suggesting possible etiological significance in mental illness (3) , At present, the role of~-endorphin and the effects of hemodialysis in chronic schizophrenia are still controversial.
The promising clinical results reported by Cade and Wagemaker have resulted in extensive interest in studying hemodialysis and other possible approaches for chronic schizophrenia. Thus, it has been reported that in chronic schizophrenic patients treated by hemofiltration the patients showed signs of morphine withdrawal (4). This type of observation seems to correlate with the removal of morphine-like substance, for instance~-en dorphin. On the other hand, it is also important to note that some centers do not observe any elevation of~-en dorphin level in the blood of chronic schizophrenic patients, nor do they find any~-endorphin in ultrafiltrate or dialysate. In our studies of using ACAC (albumin-collodion coated activated charcoal) hemoperfusion for chronic schizophrenia, we also observed signs and symptoms comparable to morphine withdrawal (5) . For instance, in a patient with 3 years of chronic schizophrenia not improved by any standard therapy and confined to hospital, during the first hemoperfusion, one hour of hemoperfusion resulted in yawning, mydriasis, shakiness, chilliness, nausea, emesis, desire to defecate, increase in systolic blood pressure and increase in pulse rate. Blood culture was negative and pyrogen tests of hemoperfusion systems were negative. In our experience of more than 40 cases of chronic renal failure, acute intoxication and liver failure patients, ACAC hemoperfusion has never resulted in these signs and symptoms. With subsequent treatment similar signs and symptoms, though less marked, were observed in each of the 6 hemoperfusion procedures. In all 6 hemoperfusions at weekly intervals, the signs and symptoms appeared very precisely at 1 hour ± 5 minutes after the initiation of hemoperfusion. If these observations can be attributed to the removal of a morphine-like substance, for instance~-endorphin, then the ability of the ACAC hemoperfusion to remove this substance is extremely effective. However, one important question that one should raise is whether these types of withdrawal symptoms could be due to the rapid removal of the neuroleptic drug, phenothiazide that most chronic schizophrenic patients are taking, even though phenothiazine are mostly tissue-bound with only an extremely small fraction in the circulation which is proteinbound.
One should take great care in not prematurely attributing the possible toxic substances, if any, in chronic schizophrenia to a specific~-endorphin.
If there are actu-ally substances causing chronic schizophrenia, there could be a large number of different types of metabolites somewhat along the lines of chronic renal failure or hepatic coma. Rigorous attempts to correlate results of treatment with~-endorphin alone may be premature. The most important criteria now is whether patients improve clinically with treatment. These clinical observations may perhaps be far more important than over-emphasizing the removal of~-endorphin.
If there are substances responsible for chronic schizophrenia and if the responsible substances can be adsorbed by activated charcoal, whether they be~-en dorphin, some type of peptides, other «middle molecules», small molecules, or loosely protein-bound molecules, then charcoal hemoperfusion may contribute much to the convenience and the case of treatment of chronic schizophrenia. However, certain cautions should be emphasized when assessing the treatment of chronic schizophrenia using charcoal hemoperfusion. Even with correct diagnosis of chronic schizophrenia, the correct criteria for selection of patients, and the correct protocol of psychiatric assessment, there are still numerous important factors. The most important of which is that at present there are at least 10 different types of charcoal hemoperfusion systems available, and the numbers are increasing. Each of these varies markedly in the following properties. 1. There are great variations in the thickness and permeability of the membrane. This can greatly affect the clearance and the permeability especially to larger molecules. 2. The total amount of charcoal used varies from 300 g to less than 100 g and the total adsorbing capacity of the different systems therefore varies. 3. The type of activated charcoal use to form the hemoperfusion systems ranges from coconut, petroleum based, to other types of organic sources. It is well known that affinity of activated charcoal for different molecules varies from one type of charcoal to another. 4. The blood compatibility of hemoperfusion devices also varies extensively. The extra cells and fibrin coating on the membrane of less blood compatible hemoperfusion systems may affect the in-vivo permeability characteristics. 5. Furthermore, some hemoperfusion systems with albumin coatings can more efficiently remove protein-bound molecules in addition to free molecules. With all these variations, it should not be too surprising in the near future to encounter conflicting results reported by different laboratories. A plea is made to define exactly the type of hemoperfusion systems used, the criteria for selection of patients and other protocols without attempting to generalize the effects of hemoperfusion on chronic schizophrenia.
In summary, the possible use of hemoperfusion for the treatment of ch:onic schizophrenia should be carefully investigated. If it is found to be useful in actually im-proving the clinical conditions of chronic schizophrenic patients, then it will be a much simpler approach than other types of blood purification procedures. On the other hand, at this early stage, a plea is made to all those using hemoperfusion to define the system they are using. Also it is hoped that no premature conclusions will be drawn and that no attempts are planned to rush prematurely into large scale treatment without first going through cautions and well designed, limited clinical trials. The selection of the sodium concentration [Na+] currently used in most centers has been largely an accident of history. In the early years of dialysis, a low dialysate [Na+] was popular because fluid removal by ultrafiltration and control of blood pressure were difficult. Limitations of membrane technology did not permit adequate diffusive ability, and it was customary and necessary to dialyze for 10 to 16 hours. Salt and water equilibration between plasma and other body fluid compartments was slow, and side effects which could be ascribed to the physical consequences of dialysis were relatively unim-255 portant. With the improvement in dialyzer design, there has been an increase in the popularity of short-term dialysis but with more dialysis-related complications (1, 2) . Attention has now shifted from the efficiency of dialysis in terms of substance removal to the ability to transfer fluid rapidly. The relevant complications can be generally considered part of dialysis disequilibrium, but consist particularly of cramps and hypotension. The pathogeneses of these are not fully understood. In part, they appear to relate to the fluid shifts that occur with rapid dialysis resulting in cellular overhydration and an apparent decrease in circulating blood volume. Alternatively, failure of physiological compensations for fluid loss, including impairment of baroreceptor function, peripheral vasoconstriction, or of myocardial chronotropic or inotropic response, may be relevant. Other possible factors are the effects of acetate infusion or of bicarbonate loss during dialysis (2) .
Dialysate Sodium Concentration
Stewart has presented the case for isonatric dialysis (± 145mEq/L) (3, 4, 5) . Assuming normal plasma proteins, this concentration would be identical to the [Na"] in plasma water. He found when this dialysate [Na"] was used, the incidence of cramps was reduced but at the expense of an increase in interdialytic weight gain, the effects on blood pressure were not discussed. The maximal rate of fluid removal during dialysis was only 0.5 Kg/hr, and this figure is not adequate for 4-hour dialysis in many non-compliant individuals who have an interdialytic weight gain of over 3 Kg. He pointed out that most dialysis units in the United Kingdom used dialysate [Na '] of less than 136 mEq/L, which we have found in an informal survey to be true also in the U.S.A. Those patients in whom isonatric dialysis results in unacceptable hypertension and thirst can be identified and treated with lower dialysate [Na "]. Others have also demonstrated the beneficial effect of higher sodium concentrations on dialysis disequilibrium, muscle cramps, hypotensive episodes, and of «restless legs» between dialyses (6, 7, 8) . Sugerman et al have suggested that high dialysate [Na-] can be used as a cheaper and easier alternative to sequential ultrafiltration and dialysis (9) . Romagnoli et al (10) suggested that in 25% of their patients a low dialysate [Na+] resulted in hypertension from increased renin production and that these patients benefited from an increase in dialysate sodium. However, the remainder did better with lower concentrations. Lackenschweiger showed that the increase in blood pressure occurring with a higher dialysate [Na '] concentration depended on the height of the blood pressure prior to increasing the sodium concentration (11) . Wilkinson (7) argued in favor of a compromise [Na"] of 136 mEq/L combined with careful blood pressure control, reflecting a balance between hypertension and the ability to ultrafilter without complications. Others have shown that a rapid increase of
